Transenterix (TRXC) Getting Somewhat Positive Media Coverage, Analysis Finds
Headlines about Transenterix (NASDAQ:TRXC) have trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Transenterix earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave press coverage about the company an impact score of 46.5758564372444 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Transenterix (NASDAQ TRXC) opened at 1.49 on Tuesday. The stock’s 50 day moving average price is $0.89 and its 200-day moving average price is $0.84. Transenterix has a one year low of $0.45 and a one year high of $2.33. The stock’s market cap is $221.32 million.
Separately, Zacks Investment Research cut Transenterix from a “buy” rating to a “sell” rating in a report on Tuesday, August 8th.
COPYRIGHT VIOLATION WARNING: “Transenterix (TRXC) Getting Somewhat Positive Media Coverage, Analysis Finds” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/09/19/transenterix-trxc-getting-somewhat-positive-media-coverage-analysis-finds.html.
TransEnterix, Inc is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company’s ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera.
Receive News & Stock Ratings for Transenterix Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transenterix Inc and related stocks with our FREE daily email newsletter.